Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0001829126-25-001934
Filing Date
2025-03-20
Accepted
2025-03-20 16:30:56
Documents
65
Period of Report
2024-12-31

Document Format Files

Seq Description Document Type Size
1 10-K titanpharma_10k.htm   iXBRL 10-K 1175326
2 EXHIBIT 10.20 titanpharma_ex10-20.htm EX-10.20 63195
3 EXHIBIT 19.1 titanpharma_ex19-1.htm EX-19.1 42224
4 EXHIBIT 23.1 titanpharma_ex23-1.htm EX-23.1 2127
5 EXHIBIT 23.2 titanpharma_ex23-2.htm EX-23.2 2425
6 EXHIBIT 31.1 titanpharma_ex31-1.htm EX-31.1 9123
7 EXHIBIT 32.1 titanpharma_ex32-1.htm EX-32.1 4437
  Complete submission text file 0001829126-25-001934.txt   5143023

Data Files

Seq Description Document Type Size
8 XBRL SCHEMA FILE ttnp-20231231.xsd EX-101.SCH 37468
9 XBRL CALCULATION FILE ttnp-20231231_cal.xml EX-101.CAL 43314
10 XBRL DEFINITION FILE ttnp-20231231_def.xml EX-101.DEF 125488
11 XBRL LABEL FILE ttnp-20231231_lab.xml EX-101.LAB 354661
12 XBRL PRESENTATION FILE ttnp-20231231_pre.xml EX-101.PRE 276408
67 EXTRACTED XBRL INSTANCE DOCUMENT titanpharma_10k_htm.xml XML 573921
Mailing Address 400 OYSTER POINT BLVD SUITE 505 SAN FRANCISCO CA 94080
Business Address 400 OYSTER POINT BLVD SUITE 505 SAN FRANCISCO CA 94080 6502444990
TITAN PHARMACEUTICALS INC (Filer) CIK: 0000910267 (see all company filings)

EIN.: 943171940 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 001-13341 | Film No.: 25756927
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)